Disease Overview：Platelet Membrane Glycoprotein Deficiency（PMGD）
Platelet membrane glycoprotein deficiency, also known as Glanzmann thrombasthenia (GT), is a rare autosomal recessive bleeding disorder caused by quantitative or qualitative defects in platelet membrane glycoproteins IIb/IIIa—critical receptors for fibrinogen binding and platelet aggregation. Patients present with mucocutaneous bleeding, epistaxis, menorrhagia, and prolonged bleeding after trauma or surgery. Diagnosis relies on flow cytometry to quantify GPIIb/IIIa expression, platelet aggregometry showing absent response to ADP, epinephrine, and collagen, and genetic testing confirming biallelic pathogenic variants in ITGA2B or ITGB3 genes. Management is supportive: antifibrinolytics (e.g., tranexamic acid), platelet transfusions for acute hemorrhage, and recombinant activated factor VII (rFVIIa) for refractory cases. Hematopoietic stem cell transplantation remains the only curative option for severe, transfusion-dependent patients.
China offers distinct advantages for GT management: leading hematology centers—including Peking Union Medical College Hospital and Shanghai Ruijin Hospital—possess extensive experience in inherited platelet disorders, advanced flow cytometry platforms, next-generation sequencing capabilities, and growing expertise in HLA-matched allogeneic HSCT with reported 5-year overall survival exceeding 85% in recent cohorts. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising clinical standards or regulatory oversight (NMPA-approved diagnostics and therapeutics). As a dedicated medical tourism agency, we facilitate seamless international care—vetting accredited hospitals, coordinating multidisciplinary hematologic evaluations, providing itemized, transparent pricing in advance, and offering end-to-end support from visa assistance to post-treatment follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Platelet Membrane Glycoprotein Defect (e.g., Glanzmann Thrombasthenia)
Non-Surgical / Conservative Management
*Target Criteria:* Mild–moderate bleeding, elective procedures, prophylaxis in high-risk settings (e.g., surgery, trauma), or patients ineligible for invasive therapy.
- •Desmopressin (DDAVP) Infusion (IV)
- •Antifibrinolytic Therapy (Tranexamic Acid)
- •Platelet Transfusion (Leukoreduced, HLA-matched if alloimmunized)
- •Baseline Diagnostic Workup (Essential for all)
- Platelet aggregation studies (ADP, epinephrine, ristocetin): $145 - Genetic sequencing (GP IIb/IIIa gene *ITGA2B/ITGB3*): $420
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Severe recurrent hemorrhage (e.g., GI, CNS), life-threatening bleeding unresponsive to transfusion, or preparation for major surgery.
- •Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Preoperative workup (ECG, CT chest/abdomen, pulmonary function, viral serologies, bone marrow biopsy): $1,850 - Conditioning regimen (fludarabine/busulfan): $2,100 - HSCT procedure + 30-day inpatient care: $38,500–$47,200
- •Splenectomy (Laparoscopic)
- Preoperative labs (CBC, coagulation panel, IgG levels): $115 - Procedure + 5-day hospitalization: $4,900–$5,700
Special / Complex Condition Management
- •Recombinant Factor VIIa (rFVIIa) for acute life-threatening bleed
- •Immunosuppression (for alloimmunized patients refractory to platelet transfusion)
- IVIG (2 g/kg over 2–5 days): $1,950
Quick Selection Guide
- •Children <12 years, mild bleeding: Start with tranexamic acid + DDAVP ($30–$80/month); avoid routine transfusion.
- •Adults, severe phenotype, matched sibling donor available: HSCT is curative—optimal despite upfront cost ($40K–$47K); long-term savings exceed lifelong transfusion support.
- •Elderly (>60) or comorbid (COPD, CKD): Avoid splenectomy/HSCT; rely on rFVIIa for emergencies + chronic antifibrinolytics ($1,300–$1,500/acute episode).
- •Budget-constrained (<$500/month): Tranexamic acid + on-demand platelet transfusion only ($280–$360/unit); prioritize genetic diagnosis ($420 one-time) to guide family counseling.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Platelet Membrane Glycoprotein Deficiency Medical Vacation Packages
Curated transparent all-inclusive packages combining Platelet Membrane Glycoprotein Deficiency treatment with China top medical destinations:
